The Cambridge, Massachusetts-based company said it expected $4 billion in revenue next year from sales of its COVID-19 shot, called Spikevax, and its respiratory syncytial virus (RSV) vaccine, which is not yet approved but expected to launch in 2024 based on positive data from a late-stage trial.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment